公开(公告)号：US5874099A

公开(公告)日：1999-02-23

申请号：US449837

申请日：1995-05-24

Applicant: Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasoohcellos ,  Michael J. Lysaght ,  Frank T. Gentile

Inventor： Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasoohcellos ,  Michael J. Lysaght ,  Frank T. Gentile

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/18 ,  A61K39/395 ,  A61K47/36 ,  A61K48/00 ,  A61L27/00 ,  C12N5/00 ,  C12N5/071 ,  C12N5/077 ,  A61K9/14

CPC classification number: A61K9/0092 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/185 ,  A61K48/00 ,  A61K9/0024 ,  A61K9/4816 ,  C12N5/0012 ,  C12N5/0062 ,  C12N5/0614 ,  C12N5/0656 ,  C12N5/0677 ,  A61K2035/126 ,  A61K2035/128 ,  C12N2510/02 ,  Y10S514/814 ,  Y10S514/866

Abstract: A method of forming an implantable and retrievable immunoisolatory vehicles is disclosed, the method comprising the steps of first forming a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of providing a biologically active product or metabolic or immunologic function, said cells being dispersed in a biocompatible hydrogel or extracellular matrix, and then forming around the core a surrounding external biocompatible thermoplastic or hydrogel jacket free of said cells projecting externally thereof, said jacket having molecular weight cutoff permitting passage of molecules to and from the core through said jacket to provide said biologically active product or function.

Abstract translation: 公开了一种形成可植入和可回收的免疫隔离剂的方法，所述方法包括以下步骤：首先形成包含至少1μl的体积和至少能够提供生物活性产物或代谢或免疫功能的至少104个细胞的核心， 所述细胞分散在生物相容的水凝胶或细胞外基质中，然后在核心周围形成周围的外部生物相容性热塑性或水凝胶套，所述周围的外部生物相容性热塑性或水凝胶护套不含外部突出的所述细胞，所述护套具有分子量截留允许分子通过和穿过芯通过 所述护套提供所述生物活性产品或功能。

公开(公告)号：US5853717A

公开(公告)日：1998-12-29

申请号：US447356

申请日：1995-05-23

Applicant: Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

Inventor： Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

IPC: A01K67/027 ,  A61K48/00 ,  A61L27/00 ,  A61L27/18 ,  A61L27/22 ,  A61L27/38 ,  C07K14/82 ,  C12N5/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  A01N63/00

CPC classification number: C12N5/0068 ,  A61L27/18 ,  A61L27/227 ,  A61L27/383 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3895 ,  C07K14/82 ,  A61K48/00 ,  C12N2510/00 ,  C12N2510/04 ,  C12N2533/30 ,  C12N2533/54 ,  C12N2533/74

Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.

公开(公告)号：US5853385A

公开(公告)日：1998-12-29

申请号：US296967

申请日：1994-08-26

Applicant: Dwaine F. Emerich ,  Patrick Aebischer ,  Jeffrey H. Kordower

Inventor： Dwaine F. Emerich ,  Patrick Aebischer ,  Jeffrey H. Kordower

IPC: A61K9/00 ,  A61K35/12 ,  A61K35/13 ,  A61M31/00

CPC classification number: A61K35/13 ,  A61K9/0085 ,  A61M31/002

Abstract: This invention relates to implantation of encapsulated PC12 cells capable of slowing or preventing the degenerative processes of Parkinson's disease by releasing factors in addition to dopamine into individuals suffering from the disease. This restorative effect continues even after the encapsulated cells are removed from the patient's brain.

Abstract translation: 本发明涉及通过将除多巴胺之外的因子释放到患有该疾病的个体中，能够减缓或预防帕金森病退行过程的包封的PC12细胞的植入。 即使在从患者的大脑中取出包封的细胞后，这种恢复效果仍然持续。

公开(公告)号：US5418154A

公开(公告)日：1995-05-23

申请号：US997770

申请日：1992-12-24

Applicant: Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

IPC: A61F2/02 ,  A61J3/07 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61J3/07 ,  A61K35/22 ,  A61K35/30 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/5089 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30 ,  Y10S530/817

Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.

Abstract translation: 包含生物材料的细长无缝胶囊通过以下方法制备，其中包括细胞悬浮液或其它生物活性因子的凝结剂和聚合物浇铸溶液通过具有至少两个同心孔的共同挤出口挤出，使得凝结剂 通过内孔挤出，并且聚合物浇铸溶液通过外孔挤出。 该方法包括在引发浇铸溶液通过相应的孔之后引发凝结剂的挤出，以形成具有弯曲且光滑的前缘形状的胶囊。 然后关闭凝结剂的输送，并且立即或在一些预定时间之后终止浇注溶液的挤出。

公开(公告)号：US5092871A

公开(公告)日：1992-03-03

申请号：US600021

申请日：1990-11-30

Applicant: Patrick Aebischer ,  Paolo Dario ,  Angelo Sabatini ,  Robert F. Valentini

Inventor： Patrick Aebischer ,  Paolo Dario ,  Angelo Sabatini ,  Robert F. Valentini

IPC: A61B17/00 ,  A61B17/11 ,  A61F2/00 ,  A61L31/04 ,  A61L31/14

CPC classification number: A61L31/14 ,  A61B17/1128 ,  A61L31/04 ,  A61L31/048 ,  A61B17/00491 ,  A61B2017/00004 ,  A61F2002/30235 ,  A61F2230/0069 ,  A61L2430/32 ,  Y10S623/92 ,  Y10S977/908

Abstract: A medical device is disclosed for use in regenerating a severed nerve, including a tubular, biocompatible, electrically-charged membrane or guidance channel, having openings adapted to receive the ends of the severed nerve and defining a lumen through which the nerve can regenerate. The electrically-charged membrane can further include a polymeric electret material that is electrically poled. A method for repairing a severed nerve is also disclosed and includes placing severed nerve ends in proximity to each other within the lumen of the guidance channel of the present invention and securing the nerve ends to the device.

Abstract translation: 公开了用于再生切断的神经的医疗装置，其包括管状的，生物相容的，带电荷的膜或引导通道，其具有适于接收切断的神经的端部并限定神经可再生的内腔的开口。 带电膜可以进一步包括电极化的聚合物驻极体材料。 还公开了修复切断的神经的方法，并且包括在本发明的引导通道的内腔内彼此靠近地设置切断的神经末端并将神经末端固定到该装置。

公开(公告)号：US5030225A

公开(公告)日：1991-07-09

申请号：US621081

申请日：1990-11-30

Applicant: Patrick Aebischer ,  Robert F. Valentini

Inventor： Patrick Aebischer ,  Robert F. Valentini

IPC: A61B17/00 ,  A61B17/11 ,  A61F2/00 ,  A61L31/04 ,  A61L31/14

CPC classification number: A61L31/14 ,  A61B17/1128 ,  A61L31/04 ,  A61L31/048 ,  A61N1/0556 ,  A61N1/36103 ,  A61B17/00491 ,  A61B2017/00004 ,  A61F2002/30235 ,  A61F2230/0069 ,  A61L2430/32 ,  Y10S977/908

Abstract: A medical device is disclosed for use in regenerating a severed nerve. The device includes an implantable, tubular, electrically-charged membrane having openings adapted to receive the ends of the severed nerve and a lumen having a diameter ranging from about 0.5 millimeters to about 2.0 centimeters to permit regeneration of the nerve therethrough. The membrane is fabricated such that an electric charge is exhibited at the inner membrane surface to stimulate regeneration by axonal sprouting and process extension. Also disclosed are methods for repairing a severed nerve and for preparing a medical device for use in regeneration of a severed nerve.

Abstract translation: 公开了用于再生切断的神经的医疗装置。 该装置包括可植入的，管状带电的膜，其具有适于接纳切断的神经的端部的开口和具有约0.5毫米至约2.0厘米的直径的内腔，以允许神经通过其再生。 制造膜，使得在内膜表面显示电荷，以通过轴突发芽和加工延伸来刺激再生。 还公开了修复切断的神经和用于制备用于再次切断的神经的医疗装置的方法。

公开(公告)号：US5011486A

公开(公告)日：1991-04-30

申请号：US273236

申请日：1988-11-18

Applicant: Patrick Aebischer ,  Anastassios N. Salessiotis

Inventor： Patrick Aebischer ,  Anastassios N. Salessiotis

IPC: A61L31/04 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61L31/16 ,  A61L31/047 ,  A61L31/048 ,  A61L31/10 ,  A61L31/146 ,  A61L2300/252 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2430/32

Abstract: Medical devices and methods employing biocompatible polymers and nerve growth-enhancing active factors are disclosed for use as guidance channels for regenerating nerves. The devices are formed from a porous, tubular membrane containing active factor incorporated within the membrane and having openings adapted to receive the ends of the severed nerve. In one aspect of the invention, the membrane has an impermeable, outer membrane surface and a porous, inner membrane surface through which the active factor can diffuse and which defines the boundary of a lumen through which said nerve may regenerate. Methods for fabricating such devices are also disclosed.

Abstract translation: 公开了使用生物相容性聚合物和神经生长增强活性因子的医疗装置和方法用作神经再生的引导通道。 该装置由多孔的管状膜形成，该多孔的管状膜含有并入膜内的活性因子并且具有适于接收切断的神经的末端的开口。 在本发明的一个方面，所述膜具有不可透过的外膜表面和多孔的内膜表面，所述活性因子可通过所述内膜表面扩散并限定所述神经可再生的内腔的边界。 还公开了制造这种装置的方法。

公开(公告)号：US20070172454A1

公开(公告)日：2007-07-26

申请号：US11622284

申请日：2007-01-11

Applicant: Nicole Deglon ,  Patrick Aebischer ,  Jean-Charles Bensadoun

Inventor： Nicole Deglon ,  Patrick Aebischer ,  Jean-Charles Bensadoun

IPC: A61K48/00 ,  A61K38/20 ,  C12N15/867

CPC classification number: A61K38/204 ,  A61K48/00

Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.

Abstract translation: 本发明涉及IL-6R / IL-6嵌合体，突变蛋白，同种型，融合蛋白，功能衍生物，活性级分或环状置换衍生物或其盐在制备用于治疗和/ 或预防亨廷顿氏病。

公开(公告)号：US06800281B2

公开(公告)日：2004-10-05

申请号：US10008610

申请日：2001-11-08

Applicant: Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

Inventor： Patrick Aebischer ,  Susan Mary Kingsman ,  Stuart Naylor ,  Nicholas Mazarakis

IPC: A61K4800

CPC classification number: C12N15/86 ,  A61K48/00 ,  C07K14/4756 ,  C12N2740/15043

Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

Abstract translation: 公开并要求保护的是用于治疗或预防神经变性疾病，病症或疾病或症状或与之相关的生理学的方法，例如治疗或预防帕金森病或与之相关的症状或生理学，例如运动缺陷或黑质纹状体变性; 或用于诱导黑质纹状体再生。 有利地，所述方法包括施用表达GDNF的慢病毒载体，例如人GDNF，或其变体，同系物，类似物或衍生物。

公开(公告)号：US6083523A

公开(公告)日：2000-07-04

申请号：US148671

申请日：1998-09-04

Applicant: Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

Inventor： Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/18 ,  A61K39/395 ,  A61K47/36 ,  A61K48/00 ,  A61L27/00 ,  C12N5/00 ,  C12N5/071 ,  C12N5/077

CPC classification number: A61K9/0092 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/185 ,  A61K48/00 ,  A61K9/0024 ,  A61K9/4816 ,  C12N5/0012 ,  C12N5/0062 ,  C12N5/0614 ,  C12N5/0656 ,  C12N5/0677 ,  A61K2035/126 ,  A61K2035/128 ,  C12N2510/02 ,  Y10S514/814 ,  Y10S514/866

Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.

Abstract translation: 用于植入到产生所需产品或提供所需代谢功能的细胞个体中的免疫分析载体。 载体由含有分离的细胞和足以维持细胞的材料的核心区域组成，以及不含分离细胞的选择性选择性生物相容的外周区域，所述细胞免疫分离核心，但提供分泌产物或代谢功能的递送， 个人